| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Screening Guidelines for Breast, Cervical, and Colorectal Cancers Expanded, Include Multiple Risk Categories HOUSTON, Tex -- October 26, 2009 -- Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical, and colorectal cancers. The new recommendations represent the first wave of an effort by M. D. Anderson to improve the effectiveness of efforts to prevent and detect cancer at its earliest, most treatable stage by reconstructing and expanding its screening, risk reduction, and diagnostic guidelines across 8 disease sites. The recommendations translate best practices in cancer prevention employed at M. D. Anderson into accessible guidelines the public can follow, with risk categories identified and information about when to begin and discontinue screening exams. “Cancer screening is not one-size-fits-all,” said Therese Bevers, MD, M. D. Anderson’s Cancer Prevention Center. “Our new risk-based recommendations are markedly more personalised and precise, offering detailed guidance than what has previously been made available to the public here or by other cancer organisations.” Until now, cancer screening recommendations were targeted largely to individuals at average risk for developing cancer based on characteristics like age, family history, or genetic predisposition. However, average risk was not previously defined and recommendations for individuals at increased or high risk were not outlined. The new screening guidelines define risk and offer recommendations for those at increased and high risk of developing cancer. For example, there are now 5 different sets of screening recommendations for those at increased risk for breast cancer; 4 categories of age-based risk recommendations for cervical cancer; and for colorectal cancer, there are 3 categories defining those at increased risk and 3 categories defining those at high risk. The new guidelines build on established cancer screening practices and now more specifically offer the following recommendations: Breast Cancer For women at increased risk, the type and frequency of exams -- including clinical breast exams, mammograms, and breast MRI -- depend on factors putting them at increased risk, including history of radiation treatment to the chest, genetic predisposition, diagnosis of lobular carcinoma in situ, Gail Model score of greater than 1.7%, or family history. Cervical Cancer Beginning at age 30, adding HPV testing is a preferred option to the Pap test, and if both are negative, a woman may go to every 3 years unless she is at increased risk based on the risk factors cited above or unless the optional HPV test was not done. Colorectal Cancer · Personal history of adenomatous polyps More knowledge about how doctors make decisions about risk levels and screening tests will give patients a deeper understanding of the disease process and enable them to put their own cancer risk in perspective, he added. “For colorectal cancer screenings, patients need to be proactive about obtaining results from their screening tests. For example, if a colonoscopy reveals polyps, it is critical for the patient to know what kind, how many, and what size, since this information factors heavily into what risk category they fall into for colorectal cancer,” Dr. Bevers said. The risk categories and related guidelines were developed by multidisciplinary panels of M. D. Anderson disease site experts across several areas, including medical oncology, surgical oncology, cancer prevention, imaging, and others. Risk-based screening guidelines for prostate, liver, skin, endometrial, and ovarian cancers are currently in development and a new online risk assessment tool integrating the new screening guidelines will be launched on the M. D. Anderson Web site in early 2010.
SOURCE: University of Texas M. D. Anderson Cancer Center
|